Nieves Martinez Lago MD PhD
@dramartinezlago
MD PhD. Medical Oncologist at University Hospital Complex of Ferrol. Gastrointestinal and endocrine tumors.
ID: 1053897615295856640
21-10-2018 06:35:46
2,2K Tweet
1,1K Followers
2,2K Following
RESERVA LA FECHA ‼32 Grupo Español de Tratamiento de Tumores Digestivos International Symposium 📅11-13 Dic. 2024 Pamplona 🗣️Punto de encuentro donde especialistas nacionales e internacionales presentarán los últimos avances en investigación y tratamiento de tumores digestivos #SomosTTD ttdgroup.org/formacion/simp…
Enhorabuena Grupo GETNE 🥰
Clinical Outcomes and Histologic Findings of pts With HCC With Durable Partial Response or Durable Stable Disease After Atezolizumab + Bevacizumab Journal of Clinical Oncology doi.org/10.1200/JCO.24… 🔎Imbrave150 & RWD 👉favorable PFS & OS + high rates of pCR in pts w/ PR for ≥6 mo ESMO - Eur. Oncology
Bispecific antibodies: advancing precision oncology Trends in Cancer doi.org/10.1016/j.trec… 👉Bispecific antibodies are on the rise with promising data 👏Excellent in depth review ESMO - Eur. Oncology
BRAF + EGFR +/- MEK inhibitors after ICI in BRAF V600E mutated & MSI CRC European Journal of Cancer doi.org/10.1016/j.ejca… 👉Lower ORR & DCR, but similar PFS & OS compared to pMMR/MSS BRAFm CRC 🧐Intersting question & reassuring data ESMO - Eur. Oncology
📢Hepatopancreaticobiliary-NET abstracts in #ESMO24 ESMO - Eur. Oncology ➡️HCC ✅LBA3 - Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study ✅LBA38 - Iparomlimab and
Trastuzumab deruxtecan in HER2+ advanced mCRC The Lancet Oncology doi.org/10.1016/S1470-… 🔎DESTINY-CRC02 phs 2, 122 pts 👉5·4 & 6·4 mg/kg 👉ORR 37·8% & 27·5% 👉mPFS 5·8 & 5·5 mo 👉mOS 13·4 mo & NE 🧐support approval for pts with HER2-positive solid tumours ESMO - Eur. Oncology
📢Gastroesophageal cancer abstracts in #ESMO24 ESMO - Eur. Oncology ✅LBA58 - A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup
📢Colorectal cancer abstracts in #ESMO24 ESMO - Eur. Oncology ✅515MO - Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI) ✅516MO - Zanidatamab (Zani) + chemotherapy (CT) in first-line
🧬Mismatch repair in pancreatic cancer JAMA Oncology ✅Although it is rare, MSI should be tested in pancreatic cancer ✅Median IO duration: 27.7 months, DCR: 80% 👉doi:10.1001/jamaoncol.2024.3651 Catherine O’Connor Emily Harrold Wungki Park, MD MS Eileen M O’Reilly #cancer #Oncology #MedX
#ESMO24 ESMO - Eur. Oncology #Barcelona is less than a week away ⏰ Abstracts drop tomorrow! 👇resharing my list of #GIcancer abstracts to follow Looking forward to practice-changing data & connecting w/ colleagues 👋 OncoAlert OncologyEducation #CRCsm #HPBCsm #ESOCsm #STCsm #PancSM #ANCsm